BetterLife Pharma Inc. (BETRF)
OTCMKTS · Delayed Price · Currency is USD
0.2300
-0.0700 (-23.33%)
Aug 10, 2026, 3:12 PM EST
BetterLife Pharma Balance Sheet
Financials in millions CAD. Fiscal year is February - January.
Millions CAD. Fiscal year is Feb - Jan.
Assets
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 30, 2026 | Jan '26 Jan 31, 2026 | Jan '25 Jan 31, 2025 | Jan '24 Jan 31, 2024 | Jan '23 Jan 31, 2023 | Jan '22 Jan 31, 2022 |
Cash & Equivalents | 0.03 | 0.01 | 0.01 | 0.04 | 0.01 | 0.17 |
Cash & Short-Term Investments | 0.03 | 0.01 | 0.01 | 0.04 | 0.01 | 0.17 |
Cash Growth | 50.42% | 53.67% | -78.12% | 350.03% | -95.21% | 12.14% |
Other Receivables | 0.01 | 0 | 0.01 | 0.04 | 0.02 | 0.32 |
Receivables | 0.01 | 0 | 0.01 | 0.04 | 0.02 | 0.32 |
Prepaid Expenses | 0.21 | 0.2 | 0.21 | 0.25 | 0.05 | 0.64 |
Total Current Assets | 0.24 | 0.22 | 0.22 | 0.32 | 0.07 | 1.14 |
Property, Plant & Equipment | - | - | - | - | - | 0.02 |
Total Assets | 0.24 | 0.22 | 0.22 | 0.32 | 0.07 | 1.16 |
Liabilities
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 30, 2026 | Jan '26 Jan 31, 2026 | Jan '25 Jan 31, 2025 | Jan '24 Jan 31, 2024 | Jan '23 Jan 31, 2023 | Jan '22 Jan 31, 2022 |
Accounts Payable | 3.93 | 3.95 | 4.5 | 4.44 | 4.9 | 3.34 |
Accrued Expenses | 1.24 | 1.32 | 1.07 | 1.6 | 1.39 | 0.14 |
Short-Term Debt | 0.77 | 0.52 | 0.41 | 0.23 | 0.19 | 0.28 |
Current Portion of Long-Term Debt | 0.16 | 0.36 | 0.87 | 0.25 | - | - |
Current Income Taxes Payable | - | - | - | - | - | 0.16 |
Other Current Liabilities | 0.55 | 0.53 | 0.7 | 0.83 | 0.67 | 0.22 |
Total Current Liabilities | 6.65 | 6.68 | 7.54 | 7.35 | 7.15 | 4.14 |
Long-Term Debt | 0.03 | 0.03 | 0.05 | 0.08 | - | 0.03 |
Other Long-Term Liabilities | - | - | - | 0.59 | 0.46 | 0.86 |
Total Liabilities | 6.68 | 6.71 | 7.59 | 8.02 | 7.61 | 5.04 |
Shareholders' Equity
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 30, 2026 | Jan '26 Jan 31, 2026 | Jan '25 Jan 31, 2025 | Jan '24 Jan 31, 2024 | Jan '23 Jan 31, 2023 | Jan '22 Jan 31, 2022 |
Common Stock | 82.58 | 81.96 | 79.97 | 78.46 | 76.57 | 75.38 |
Retained Earnings | -120.7 | -120.09 | -118.6 | -115.08 | -112.19 | -103.17 |
Comprehensive Income & Other | 28.39 | 28.35 | 27.95 | 25.81 | 24.89 | 23.91 |
Total Common Equity | -9.73 | -9.78 | -10.68 | -10.81 | -10.73 | -3.88 |
Minority Interest | 3.29 | 3.3 | 3.32 | 3.11 | 3.19 | - |
Shareholders' Equity | -6.43 | -6.49 | -7.36 | -7.7 | -7.53 | -3.88 |
Total Liabilities & Equity | 0.24 | 0.22 | 0.22 | 0.32 | 0.07 | 1.16 |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 30, 2026 | Jan '26 Jan 31, 2026 | Jan '25 Jan 31, 2025 | Jan '24 Jan 31, 2024 | Jan '23 Jan 31, 2023 | Jan '22 Jan 31, 2022 |
Total Debt | 0.96 | 0.9 | 1.33 | 0.56 | 0.19 | 0.31 |
Net Cash (Debt) | -0.93 | -0.89 | -1.32 | -0.52 | -0.18 | -0.14 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share | -0.01 | -0.01 | -0.01 | -0.00 | -0.00 | -0.00 |
Filing Date Shares Outstanding | 161.89 | 161.79 | 145.49 | 117.08 | 108.68 | 84.4 |
Total Common Shares Outstanding | 161.79 | 151.9 | 129.57 | 115.83 | 90.1 | 85.24 |
Working Capital | -6.41 | -6.46 | -7.31 | -7.02 | -7.07 | -3 |
Book Value Per Share | -0.06 | -0.06 | -0.08 | -0.09 | -0.12 | -0.05 |
Tangible Book Value | -9.73 | -9.78 | -10.68 | -10.81 | -10.73 | -3.88 |
Tangible Book Value Per Share | -0.06 | -0.06 | -0.08 | -0.09 | -0.12 | -0.05 |
Machinery | - | - | - | - | - | 0.04 |